Business Description
VYNE Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US5868581027
Description
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 435.76 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -7.57 | |||||
| Beneish M-Score | -3.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -84.8 | |||||
| 3-Year EBITDA Growth Rate | 72.7 | |||||
| 3-Year EPS without NRI Growth Rate | 65.2 | |||||
| 3-Year FCF Growth Rate | 68.1 | |||||
| 3-Year Book Growth Rate | -26.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.24 | |||||
| 9-Day RSI | 52.38 | |||||
| 14-Day RSI | 51.71 | |||||
| 6-1 Month Momentum % | 7.08 | |||||
| 12-1 Month Momentum % | -44.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.73 | |||||
| Quick Ratio | 12.73 | |||||
| Cash Ratio | 12.37 | |||||
| Days Sales Outstanding | 212.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -80.4 | |||||
| Shareholder Yield % | -0.91 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -6900.71 | |||||
| Net Margin % | -6710.38 | |||||
| FCF Margin % | -5976.65 | |||||
| ROE % | -81.22 | |||||
| ROA % | -65.28 | |||||
| ROIC % | -823.13 | |||||
| ROC (Joel Greenblatt) % | -14134.78 | |||||
| ROCE % | -80.96 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 23.34 | |||||
| PB Ratio | 0.41 | |||||
| Price-to-Tangible-Book | 0.41 | |||||
| EV-to-EBIT | 1.94 | |||||
| EV-to-Forward-EBIT | -0.1 | |||||
| EV-to-EBITDA | 1.94 | |||||
| EV-to-Forward-EBITDA | -0.1 | |||||
| EV-to-Revenue | -133.64 | |||||
| EV-to-Forward-Revenue | 0.19 | |||||
| EV-to-FCF | 2.38 | |||||
| Price-to-Net-Current-Asset-Value | 0.42 | |||||
| Price-to-Net-Cash | 0.43 | |||||
| Earnings Yield (Greenblatt) % | 51.55 | |||||
| FCF Yield % | -69.67 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers